Small datasets to develop and validate prognostic models may be a necessary evil to study rare tumours

Eur J Cancer. 2016 Feb:54:169-171. doi: 10.1016/j.ejca.2015.10.062. Epub 2015 Dec 28.

Authors

Sara Valpione¹, Simone Mocellin², Luca Giovanni Campana²

Affiliations

¹ The Christie Foundation Trust, Wilmslow Rd, Manchester, M20 4BX, United Kingdom; Department of Surgery, Oncology and Gastroenterology, University of Padova, 64 Gattamelata St, 35128, Padova, Italy. Electronic address: sara.valpione@unipd.it.
² Department of Surgery, Oncology and Gastroenterology, University of Padova, 64 Gattamelata St, 35128, Padova, Italy.

PMID: 26739580
DOI: 10.1016/j.ejca.2015.10.062

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Decision Support Techniques*
Female
Humans
Male
Melanoma / drug therapy*
Melanoma / secondary*
Precision Medicine*
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology*

Substances

Antibodies, Monoclonal
Antineoplastic Agents